Subscribe to RSS
DOI: 10.1055/s-0041-1723799
Type 2B von Willebrand Disease in Pregnancy: A Systematic Literature Review
Funding None.![](https://www.thieme-connect.de/media/sth/202102/lookinside/thumbnails/10-1055-s-0041-1723799_02857-1.jpg)
Abstract
Our objective was to review the maternal characteristics and obstetric complications in women with type 2B von Willebrand disease (VWD). A systematic literature search was conducted using PubMed, Scopus, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov. We included all publications that addressed type 2B VWD in pregnancy. Our primary and secondary outcomes were incidence of postpartum hemorrhage (PPH) and incidence of thrombocytopenia in pregnancy. Two reviewers independently identified eligible studies and abstracted data including maternal characteristics, hematologic characteristics, treatment, and delivery outcomes. Twenty studies met inclusion criteria. There were 27 women (32 pregnancies) with type 2B VWD. Primary PPH was reported in 9/20 women (45%) and secondary PPH was reported in 6/13 women (46%). Thrombocytopenia in pregnancy was present in 27/28 women (96%); 23/27 women (85%) had platelet count <100 × 109/L, mean 33.7 ± 22.7 × 109/L. Factor concentrate treatment was administered before delivery (n = 16) and postpartum (n = 18), some women received both. Seventeen deliveries required blood products postpartum with 13/17 (76%) platelet transfusions and 6/17 (35%) red blood cell transfusions. No maternal mortality was reported. Women with type 2B VWD have significant morbidity in pregnancy related to high incidence of severe thrombocytopenia and primary and secondary PPH.
Authors' Contributions
M.M.M. and T.K. contributed toward the acquisition of data. M.M.M., T.K., N.D., K.L., M.L.R., D.W.S, and H.B.A. did the analysis and interpretation of data, drafted the manuscript and finally approved the version to be published. They also agreed to be accountable for all aspects of the study.
Note
The work was presented at American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting, poster presentation April 25th, 2020, Seattle, WA—presented virtually due to COVID-19.
Publication History
Article published online:
26 February 2021
© 2021. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Sadler JE, Budde U, Eikenboom JC. et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4 (10) 2103-2114
- 2 Nichols WL, Hultin MB, James AH. et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (02) 171-232
- 3 Casonato A, Daidone V, Galletta E, Bertomoro A. Type 2B von Willebrand disease with or without large multimers: a distinction of the two sides of the disorder is long overdue. PLoS One 2017; 12 (06) e0179566
- 4 Kruse-Jarres R, Johnsen JM. How I treat type 2B von Willebrand disease. Blood 2018; 131 (12) 1292-1300
- 5 Randi AM, Rabinowitz I, Mancuso DJ, Mannucci PM, Sadler JE. Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences. J Clin Invest 1991; 87 (04) 1220-1226
- 6 Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood 1982; 59 (06) 1272-1278
- 7 Sadler JE, Mannucci PM, Berntorp E. et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84 (02) 160-174
- 8 Drury-Stewart DN, Lannert KW, Chung DW. et al. Complex changes in von Willebrand factor-associated parameters are acquired during uncomplicated pregnancy. PLoS One 2014; 9 (11) e112935
- 9 Federici AB, Mannucci PM, Castaman G. et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 113 (03) 526-534
- 10 Ranger A, Manning RA, Lyall H, Laffan MA, Millar CM. Pregnancy in type 2B VWD: a case series. Haemophilia 2012; 18 (03) 406-412
- 11 Lee CA, Chi C, Pavord SR. et al; UK Haemophilia Centre Doctors' Organization. The obstetric and gynaecological management of women with inherited bleeding disorders—review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization. Haemophilia 2006; 12 (04) 301-336
- 12 Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 2011; 113 (01) 3-13
- 13 Committee on Practice Bulletins-Obstetrics. 183: postpartum hemorrhage. Obstet Gynecol 2017; 130 (04) e168-e186
- 14 Committee on Practice Bulletins—Obstetrics. 207: thrombocytopenia in pregnancy. Obstet Gynecol 2019; 133 (03) e181-e193
- 15 Wiedmeier SE, Henry E, Sola-Visner MC, Christensen RD. Platelet reference ranges for neonates, defined using data from over 47,000 patients in a multihospital healthcare system. J Perinatol 2009; 29 (02) 130-136
- 16 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6 (07) e1000097
- 17 Zembala-Szczerba M, Huras H. Von Willebrand disease from the viewpoint of obstetrician—case studies. Ginekologia i Poloznictwo 2015; 35: 88-94
- 18 Chen PH, Hsien-Liu. Lee SL, Chang CY, Chang CC. Ovarian hyperstimulation syndrome associated with von Willebrand's disease. Taiwan J Obstet Gynecol 2011; 50 (02) 217-219
- 19 Hepner DL, Tsen LC. Severe thrombocytopenia, type 2B von Willebrand disease and pregnancy. Anesthesiology 2004; 101 (06) 1465-1467
- 20 Mathew P, Greist A, Maahs JA, Lichtenberg EC, Shapiro AD. Type 2B vWD: the varied clinical manifestations in two kindreds. Haemophilia 2003; 9 (01) 137-144
- 21 Pareti FI, Federici AB, Cattaneo M, Mannucci PM. Spontaneous platelet aggregation during pregnancy in a patient with von Willebrand disease type IIB can be blocked by monoclonal antibodies to both platelet glycoproteins Ib and IIb/IIIa. Br J Haematol 1990; 75 (01) 86-91
- 22 Valster FA, Feijen HL, Hutten JW. Severe thrombocytopenia in a pregnant patient with platelet-associated IgM and known von Willebrand's disease; a case report. Eur J Obstet Gynecol Reprod Biol 1990; 36 (1-2): 197-201
- 23 Rick ME, Williams SB, Sacher RA, McKeown LP. Thrombocytopenia associated with pregnancy in a patient with type IIB von Willebrand's disease. Blood 1987; 69 (03) 786-789
- 24 Casonato A, Sartori MT, Bertomoro A, Fede T, Vasoin F, Girolami A. Pregnancy-induced worsening of thrombocytopenia in a patient with type IIB von Willebrand's disease. Blood Coagul Fibrinolysis 1991; 2 (01) 33-40
- 25 Burlingame J, McGaraghan A, Kilpatrick S, Hambleton J, Main E, Laros RK. Maternal and fetal outcomes in pregnancies affected by von Willebrand disease type 2. Am J Obstet Gynecol 2001; 184 (02) 229-230
- 26 Biguzzi E, Siboni SM, Ossola MW, Zaina B, Migliorini AC, Peyvandi F. Management of pregnancy in type 2B von Willebrand disease: case report and literature review. Haemophilia 2015; 21 (01) e98-e103
- 27 Baaij M, van Galen KP, Urbanus RT, Nigten J, Eikenboom JH, Schutgens RE. First report of inhibitory von Willebrand factor alloantibodies in type 2B von Willebrand disease. Br J Haematol 2015; 171 (03) 424-427
- 28 Castaman G, James PD. Pregnancy and delivery in women with von Willebrand disease. Eur J Haematol 2019; 103 (02) 73-79
- 29 Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. Pregnancy in women with von Willebrand's disease or factor XI deficiency. Br J Obstet Gynaecol 1998; 105 (03) 314-321
- 30 Berg CJ, Mackay AP, Qin C, Callaghan WM. Overview of maternal morbidity during hospitalization for labor and delivery in the United States: 1993-1997 and 2001-2005. Obstet Gynecol 2009; 113 (05) 1075-1081
- 31 Makhamreh MM, Kass SL, Russo ML, Ahmadzia H, Al-Kouatly HB. Type 3 von Willebrand disease in pregnancy: a systematic literature review. Am J Perinatol 2019; (e-pub ahead of print). DOI: 10.1055/s-0039-1700541.
- 32 Punt MC, Waning ML, Mauser-Bunschoten EP. et al. Maternal and neonatal bleeding complications in relation to peripartum management in women with Von Willebrand disease: a systematic review. Blood Rev 2020; 39: 100633
- 33 Grover N, Boama V, Chou MR. Pseudo (platelet-type) von Willebrand disease in pregnancy: a case report. BMC Pregnancy Childbirth 2013; 13 (01) 16
- 34 Martingano D, Guan X, Martingano FX. Management of pregnancy and emergency caesarean delivery in a patient with type IIB von Willebrand disease and severe preeclampsia: a case report and literature review. Obstet Med 2018; 11 (02) 92-94
- 35 McLaughlin D, Kerr R. Management of type 2B von Willebrand disease during pregnancy. Acta Haematol 2017; 137 (02) 89-92
- 36 Langer F, Obser T, Oyen F. et al. Characterisation of the p.A1461D mutation causing von Willebrand disease type 2B with severe thrombocytopenia, circulating giant platelets, and defective α-granule secretion. Thromb Haemost 2014; 111 (04) 777-779
- 37 Takafuta T, Fujimura K, Shimomura T. et al. Precise diagnosis by gene analysis and successful management of delivery in three patients with type IIB von Willebrand disease. Int J Hematol 1994; 60 (02) 163-172
- 38 Ieko M, Sakurama S, Sagawa A. et al. Effect of a factor VIII concentrate on type IIB von Willebrand's disease-associated thrombocytopenia presenting during pregnancy in identical twin mothers. Am J Hematol 1990; 35 (01) 26-31
- 39 Giles AR, Hoogendoorn H, Benford K. Type IIB von Willebrand's disease presenting as thrombocytopenia during pregnancy. Br J Haematol 1987; 67 (03) 349-353
- 40 Conti M, Mari D, Conti E, Muggiasca ML, Mannucci PM. Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol 1986; 68 (02) 282-285
- 41 Peyvandi F, Kouides P, Turecek PL, Dow E, Berntorp E. Evolution of replacement therapy for von Willebrand disease: from plasma fraction to recombinant von Willebrand factor. Blood Rev 2019; 38: 100572